ACSL4 and osteosarcoma: No systemic toxicity was observed.<h4>Conclusion</h4>These findings establish LF3 as a dual-targeting agent that overcomes osteosarcoma through coordinated Wnt suppression and ferroptosis activation via the HO-1/ACSL4 axis, providing a novel therapeutic strategy for chemoresistant osteosarcoma.